Zelda Therapeutics Medical Marijuana and Autism Consensus Symposium 2019

Event Information

Share this event

Date and Time



Quorum at the University City Science Center

3675 Market Street

Philadelphia, PA 19104

View Map

Event description


Zelda Therapeutics Medical Marijuana and Autism Consensus Symposium 2019
This symposium is a science-focused seminar of medical professionals with experience in potential benefits/risks associated with the use of medical marijuana to treat a range of behaviors in Autism Spectrum Disorder (ASD). Dr. Rachel Levine, Secretary of Health for the Commonwealth of Pennsylvania, will present an update on the Pennsylvania Medical Marijuana Program. We will highlight some of the preliminary results of the current Children’s Hospital of Philadelphia observational study examining the landscape of current medical cannabis use in ASD. There will be international experts presenting information on autism and treatment with medical cannabis. Parents/caregivers of children diagnosed with ASD who have participated in the observational trial are encouraged to attend the entire day, but there will be a specific breakout session at the end of the conference for them. This breakout session will share with parents/caregivers preliminary results of the observational study that they participated in. There will also be a panel of medical professionals and parents to help answer questions. Note: If your child was enrolled in the study and you are not able to attend in person please contact us regarding remote access to the sessions.


7:45 AM - 8:30 AM, Registration & Continental Breakfast

8:30 AM, Welcome Remarks by Dr. Meghan Thomas

9:00 AM - 9:40 AM, Dr. Rachel Levine
Overview of Pennsylvania Medical Marijuana Program

9:45 AM - 10:15 AM, Dr. Benjamin Yerys
Overview of ASD Symptoms Targeted for Treatment
Current Pharmacologic Treatment Approaches to ASD, Risks and Benefits, Successes and Failures

10:15 AM - 10:30 AM, Break

10:30 AM - 11:00 AM, Dr. Ethan Russo
Overview of Medicinal Cannabis and Its Impact Across Various Indications. Where is the Sector Heading from a Regulatory Perspective?

11:00 AM - 11:30 AM, Dr. Dustin Sulak Summary of Preclinical and Clinical Trials (Observational and Clinical) for Autism Medical Cannabis and ASD Plus Other Indications. How/Where Do We Target Future Research Efforts?

11:30 AM - 12:00 PM, Dr. Bonni Goldstein
Experiences in Treating ASD Patients with Medical Cannabis

12:00 PM - 12:30 PM, Lunch/Networking

12:30 PM - 1:00 PM, Dr. Athena Zuppa
Summary of Key Outcomes to CHOP Observational Trial. Current Utilization in ASD (CHOP Study) to include PK Information

1:00 PM - 1:30 PM, Dr. Doris Trauner
Update on Current CBD and Autism Trial

1:30 PM - 2:00 PM, Dr. Meghan Thomas
What is Australia Doing? Zelda-sponsored Phase I/II ASD Clinical Trial

2:00 PM - 3:00 PM, Panel Discussion {Lead by Dr. F. Xavier Castellanos}
Dr. Doris Trauner & Dr. Athena Zuppa
Can Collaboration Help Us Transcend Regulatory and Research Challenges? Who's on First?

3:00 PM - 3:15 PM, Closing Remarks by Dr. Meghan Thomas

3:15 PM - 3:30 PM, Break

Research Study Parent Session

3:30 PM, Welcome
3:35 PM - 4:05 PM, Overview of CHOP Study and Presentation of General Interim Results to include Disease Burden of Children with ASD, Dosing Variability, Dosing Patterns and Dose Related to Efficacy (Educational Component) Dr. Benjamin Yerys

4:05 PM - 4:35 PM, Parent/Provider Panel Discussion
4:35 PM - 4:45 PM, Questions
4:45 PM - 5:00 PM, Closing Remarks

Who Should Attend

  • Medical professionals treating pediatric patients with ASD

  • Medical professionals who are involved in or have a strong interest in treating ASD with medical cannabis

  • Medical staff at medical marijuana dispensaries

  • Parents/caregivers who are enrolled in the current CHOP Medical Cannabis and Autism study

  • Parents/caregivers who have child diagnosed with ASD and are seeking additional information regarding treatment with medical cannabis

Goals or Objectives

  1. Describe the current medical marijuana program in Pennsylvania

  2. Identify the proper forms of medical marijuana that a patient may purchase in Pennsylvania

  3. Understand who is authorized to recommend medical marijuana in Pennsylvania

  4. List the most common behavioral conditions in ASD patients which are treated with medical marijuana

  5. Understand the current pharmacologic treatments in ASD

  6. Explain the physiologic mechanisms in treating ASD with medical cannabis

  7. Describe areas for future research

  8. Explain preliminary results of the CHOP study

  9. Understand the current utilization of medical marijuana in the ASD population

  10. Identify research challenges and solutions

There is no cost to attend this symposium. Registration includes full day educational sessions and meals. Walk in or onsite registration will not be accepted.

#zeldatherapeutics #medicinalcannabis #autism #clinicaltrial #ZLD

No childcare services are available onsite.

Press attendance requires prior written approval. Contact support@albrechtevents.com with inquiries.

Need a hotel room?
We have secured a block of rooms at The Inn at Penn, a Hilton Hotel for a disocunted rate. Please call Kaitlyn Devlin at 215-823-6202 and ask for the Autism Symposium rate.

Date and Time


Quorum at the University City Science Center

3675 Market Street

Philadelphia, PA 19104

View Map

Save This Event

Event Saved